Maxim Group Comments on Omeros (OMER) Following New Omidria Supply Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Omeros Corp. (OMER), Hospira (HSP) Enter Supply Agreement for Omidria
October 7, 2014 7:03 AM EDTOn October 3, 2014, Omeros Corporation (Nasdaq: OMER), Hospira S.p.A., and Hospira Worldwide, Inc. (NYSE: HSP) entered into a Commercial Supply Agreement (the Supply Agreement), pursuant to which Hospira will act as a non-exclusive supplier of Omeros product Omidria for commercial sale in the United States and the European Union (the Territory).
Pursuant to the Supply Agreement, Hospira has agreed to manufacture and supply, and Omeros has agreed to purchase, a minimum percentage of Omeros requirements of Omidria for commercial sales and clinical supplies for the development of additional... More
